Sun Pharmaceutical Latest Updates

recently reported a 20% year-on-year drop in its consolidated net profit for the first quarter, though this was primarily due to a significant one-time charge. Despite the decline in reported profit, the company's total income for the quarter actually increased, indicating steady growth across its key markets. The company's performance was bolstered by a strong showing in its India business and the launch of a new product in the US. Sun Pharma introduced "LEQSELVI," a new treatment for severe alopecia areata, in the US market, which is expected to strengthen its innovative medicines and dermatology portfolios. While the pharmaceutical sector remains exempt from the US's new general tariff levy, the company's management is monitoring the situation. Sun Pharma's leadership has stated that they do not have plans to expand their manufacturing base in the US, as their current capacity there is sufficient. The company's domestic business and new product launches are expected to be key drivers of future growth.